JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series
- 1Department of Dermatology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, People’s Republic of China
- 2Ruijin-Yatsen Joint Laboratory, Ruijin Hospital, School of Medicine, Shanghai Jiao Tong University, Shanghai, People’s Republic of China
Abstract
Background: Eczematous eruption (EE) is a paradoxical adverse event during interleukin-17A (IL-17A) inhibitor therapy for psoriasis and may require modification or discontinuation of biologic therapy. However, evidence guiding its management remains limited.
Methods: We retrospectively reviewed 13 patients with psoriasis who developed EE during IL-17A inhibitor therapy and subsequently received selective Janus kinase 1 inhibitors (JAK1i; upadacitinib, n=11; abrocitinib, n=2).
Results: JAK1i treatment resulted in rapid clinical improvement, with mean Eczema Area and Severity Index (EASI) scores decreasing from 14.7 to 3.0 and pruritus visual analogue scale scores from 9.1 to 2.2 after 4 weeks; all patients showed marked clinical improvement by week 8. During a median follow-up of 68 weeks from JAK1i initiation, subsequent psoriasis treatment was individualized according to disease course, with heterogeneous subsequent treatment strategies across patients.
Conclusion: These findings support the potential use of selective JAK1 inhibitors for rapidly controlling IL-17A inhibitor-associated EE, with subsequent psoriasis management individualized according to the clinical course.
Related
- Clinical Outcomes Following Mandatory Switching to an Adalimumab Biosimilar in Patients with Psoriasis: A Real-world Single-centre Experience.
- Less Is More: Cost-Effective Psoriasis Management via Disease-Driven Dosing of IL-17/IL-23 Inhibitors.
- Adjusted Comparative Treatment Persistence of IL-23p19 Versus IL-17 Pathway Inhibitors in Adults With Plaque Psoriasis: A Systematic Review and Exploratory Meta-analysis of Real-World Time-to-Discontinuation Estimates
- Tumor necrosis factor inhibitors and cardiovascular outcomes in adults with moderate-to-severe plaque psoriasis: a systematic review and meta-analysis☆
- Targeting Macrophage STING O-GlcNAcylation via Small-Molecule Allosteric Modulation for Psoriasis Therapy.
BibTeX
@article{zhang2026jak1,
title = {{JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series}},
author = {Li Zhang and Jingwen Wu and Jie Zheng and Lihong Chen and Youcong Wang and Xia Li},
journal = {Psoriasis: Targets and Therapy},
year = {2026},
month = oct,
doi = {10.2147/ptt.s640212},
url = {https://doi.org/10.2147/ptt.s640212},
note = {CC BY-NC 4.0},
}
RIS
TY - JOUR
TI - JAK1 Inhibitors for Eczematous Eruptions Following Anti-IL-17A Therapy in Psoriasis: A Case Series
AU - Li Zhang
AU - Jingwen Wu
AU - Jie Zheng
AU - Lihong Chen
AU - Youcong Wang
AU - Xia Li
PY - 2026
DA - 2026/10/31
JO - Psoriasis: Targets and Therapy
DO - 10.2147/ptt.s640212
UR - https://doi.org/10.2147/ptt.s640212
AB - Background: Eczematous eruption (EE) is a paradoxical adverse event during interleukin-17A (IL-17A) inhibitor therapy for psoriasis and may require modification or discontinuation of biologic therapy. However, evidence guiding its management remains limited. Methods: We retrospectively reviewed 13 patients with psoriasis who developed EE during IL-17A inhibitor therapy and subsequently received selective Janus kinase 1 inhibitors (JAK1i; upadacitinib, n=11; abrocitinib, n=2). Results: JAK1i treatment resulted in rapid clinical improvement, with mean Eczema Area and Severity Index (EASI) scores decreasing from 14.7 to 3.0 and pruritus visual analogue scale scores from 9.1 to 2.2 after 4 weeks; all patients showed marked clinical improvement by week 8. During a median follow-up of 68 weeks from JAK1i initiation, subsequent psoriasis treatment was individualized according to disease course, with heterogeneous subsequent treatment strategies across patients. Conclusion: These findings support the potential use of selective JAK1 inhibitors for rapidly controlling IL-17A inhibitor-associated EE, with subsequent psoriasis management individualized according to the clinical course.
SN - 2230-326X
ER -